본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

Journal of the American Geriatrics Society v.65 no.1, 2017년, pp.35 - 41   SCI SCIE SSCI
본 등재정보는 저널의 등재정보를 참고하여 보여주는 베타서비스로 정확한 논문의 등재여부는 등재기관에 확인하시기 바랍니다.

Influence of Competing Risks on Estimating the Expected Benefit of Warfarin in Individuals with Atrial Fibrillation Not Currently Taking Anticoagulants: The Anticoagulation and Risk Factors in Atrial Fibrillation Study

Ashburner, Jeffrey M. (Division of Research, Kaiser Permanente Northern California, Oakland, California ); Go, Alan S. (Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts ); Chang, Yuchiao (Department of Medicine, University of California, San Francisco, San Francisco, California ); Fang, Margaret C. (Epidemiology Department, School of Public Health, Boston University, Boston, Massachusetts ); Fredman, Lisa (Department of Environmental and Occupational Health, Milken Institute, School of Public Health, George Washington University, Washington, District of Columbia ); Applebaum, Katie M. (Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts ); Singer, Daniel E. ( );
  • 초록  

    Objectives To provide greater understanding of the “real world” effect of anticoagulation on stroke risk over several years. Design Cohort study. Setting Anticoagulation and Risk Factors in Atrial Fibrillation Study community‐based cohort. Participants Adults with nonvalvular atrial fibrillation (AF) between 1996 and 2003 (13,559). Measurements All events were clinician adjudicated. Extended Cox regression with longitudinal warfarin exposure was used to estimate cause‐specific hazard ratios (HRs) for thromboembolism and the competing risk event (all cause death). The Fine and Gray subdistribution regression approach was used to estimate this association while accounting for competing death events. As a secondary analysis, follow‐up was limited to 1, 3, and 5 years. Results The rate of death was much higher in the group not taking warfarin (8.1 deaths/100 person‐years (PY)) than in the group taking warfarin (5.5 deaths/100 PY). The cause‐specific HR indicated a large reduction in thromboembolism with warfarin use (adjusted HR = 0.57, 95% confidence interval (CI) = 0.50–0.65), although this association was substantially attenuated after accounting for competing death events (adjusted HR = 0.87, 95% CI = 0.77–0.99). In analyses limited to 1 year of follow‐up, with fewer competing death events, the results for models that did and did not account for competing risks were similar. Conclusion Analyses accounting for competing death events may provide a more‐realistic estimate of the longer‐term stroke prevention benefits of anticoagulants than traditional noncompeting risk analyses for individuals with AF, particularly those who are not currently treated with anticoagulants.


  • 주제어

    anticoagulation .   stroke .   atrial fibrillation.  

 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • 원문이 없습니다.
유료다운로드

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기